Limits...
Novel combination of serum microRNA for detecting breast cancer in the early stage.

Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu C, Fujiwara Y, Kinoshita T, Tamura K, Ochiya T - Cancer Sci. (2016)

Bottom Line: The training cohort was used to identify a combination of miRNA that could detect breast cancer, and the test cohort was used to validate that combination. miRNA expressions were compared between patients with breast cancer and non-breast cancer, and a combination of five miRNA (miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p) was found to be able to detect breast cancer.This combination had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% for breast cancer in the test cohort.In addition, this combination could detect early stage breast cancer (sensitivity of 98.0% for Tis).

View Article: PubMed Central - PubMed

Affiliation: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Show MeSH

Related in: MedlinePlus

Cancer specificity of the diagnostic index using the combination of miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p in the test cohort. (a) Training cohort. Patients with breast cancer (n = 74), non‐cancer controls (n = 1493), patients with other types of cancers (n = 451) and patients with non‐breast benign diseases (n = 63) were included. (b) Test cohort. Patients with breast cancer (n = 1206), non‐cancer controls (n = 1343) and patients with benign breast diseases (n = 54) were included. BC, breast cancer; BeB, benign breast diseases; BeO, benign pancreas/biliary tract/prostate diseases; BilC, biliary cancer; CC, colorectal cancer; EC, esophageal cancer; GC, gastric cancer; H, healthy volunteer; HC, hepatic cancer; PC, pancreas cancer; PRC, prostate cancer.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4814263&req=5

cas12880-fig-0002: Cancer specificity of the diagnostic index using the combination of miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p in the test cohort. (a) Training cohort. Patients with breast cancer (n = 74), non‐cancer controls (n = 1493), patients with other types of cancers (n = 451) and patients with non‐breast benign diseases (n = 63) were included. (b) Test cohort. Patients with breast cancer (n = 1206), non‐cancer controls (n = 1343) and patients with benign breast diseases (n = 54) were included. BC, breast cancer; BeB, benign breast diseases; BeO, benign pancreas/biliary tract/prostate diseases; BilC, biliary cancer; CC, colorectal cancer; EC, esophageal cancer; GC, gastric cancer; H, healthy volunteer; HC, hepatic cancer; PC, pancreas cancer; PRC, prostate cancer.

Mentions: Using Fisher's linear discriminant analysis, we designed comprehensive discriminants with 1–5 miRNA in the training cohort (breast cancer versus non‐cancer or other cancer/non‐breast benign diseases) and validated them in the test cohort. The analysis identified a combination of five miRNA (miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p) that showed the best discrimination in both the training cohort and test cohort. The expression levels of these five miRNA are presented in Figure 1. The diagnostic index was calculated using the following formula: (0.25 × miR‐1246) + (0.49 × miR‐1307‐3p) − (1.06 × miR‐4634) + (1.89 × miR‐6875‐5p) + (0.31 × miR‐6861‐5p) − 13.94. In the training cohort, the diagnostic index showed a sensitivity of 87.8%, specificity of 78.5% and accuracy of 78.7%. Although the serum samples of breast cancer patients in the test cohort were independent from those in the training cohort, the diagnostic index showed high performance (Fig. 2a,b), with a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% (Table 2). The receiver operating characteristic curve of the test cohort is presented in Figure 3. The area under the curve (AUC) was 0.971. The specificity and AUC were calculated for the discrimination of breast cancer from the non‐cancer controls.


Novel combination of serum microRNA for detecting breast cancer in the early stage.

Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu C, Fujiwara Y, Kinoshita T, Tamura K, Ochiya T - Cancer Sci. (2016)

Cancer specificity of the diagnostic index using the combination of miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p in the test cohort. (a) Training cohort. Patients with breast cancer (n = 74), non‐cancer controls (n = 1493), patients with other types of cancers (n = 451) and patients with non‐breast benign diseases (n = 63) were included. (b) Test cohort. Patients with breast cancer (n = 1206), non‐cancer controls (n = 1343) and patients with benign breast diseases (n = 54) were included. BC, breast cancer; BeB, benign breast diseases; BeO, benign pancreas/biliary tract/prostate diseases; BilC, biliary cancer; CC, colorectal cancer; EC, esophageal cancer; GC, gastric cancer; H, healthy volunteer; HC, hepatic cancer; PC, pancreas cancer; PRC, prostate cancer.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4814263&req=5

cas12880-fig-0002: Cancer specificity of the diagnostic index using the combination of miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p in the test cohort. (a) Training cohort. Patients with breast cancer (n = 74), non‐cancer controls (n = 1493), patients with other types of cancers (n = 451) and patients with non‐breast benign diseases (n = 63) were included. (b) Test cohort. Patients with breast cancer (n = 1206), non‐cancer controls (n = 1343) and patients with benign breast diseases (n = 54) were included. BC, breast cancer; BeB, benign breast diseases; BeO, benign pancreas/biliary tract/prostate diseases; BilC, biliary cancer; CC, colorectal cancer; EC, esophageal cancer; GC, gastric cancer; H, healthy volunteer; HC, hepatic cancer; PC, pancreas cancer; PRC, prostate cancer.
Mentions: Using Fisher's linear discriminant analysis, we designed comprehensive discriminants with 1–5 miRNA in the training cohort (breast cancer versus non‐cancer or other cancer/non‐breast benign diseases) and validated them in the test cohort. The analysis identified a combination of five miRNA (miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p) that showed the best discrimination in both the training cohort and test cohort. The expression levels of these five miRNA are presented in Figure 1. The diagnostic index was calculated using the following formula: (0.25 × miR‐1246) + (0.49 × miR‐1307‐3p) − (1.06 × miR‐4634) + (1.89 × miR‐6875‐5p) + (0.31 × miR‐6861‐5p) − 13.94. In the training cohort, the diagnostic index showed a sensitivity of 87.8%, specificity of 78.5% and accuracy of 78.7%. Although the serum samples of breast cancer patients in the test cohort were independent from those in the training cohort, the diagnostic index showed high performance (Fig. 2a,b), with a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% (Table 2). The receiver operating characteristic curve of the test cohort is presented in Figure 3. The area under the curve (AUC) was 0.971. The specificity and AUC were calculated for the discrimination of breast cancer from the non‐cancer controls.

Bottom Line: The training cohort was used to identify a combination of miRNA that could detect breast cancer, and the test cohort was used to validate that combination. miRNA expressions were compared between patients with breast cancer and non-breast cancer, and a combination of five miRNA (miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p) was found to be able to detect breast cancer.This combination had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% for breast cancer in the test cohort.In addition, this combination could detect early stage breast cancer (sensitivity of 98.0% for Tis).

View Article: PubMed Central - PubMed

Affiliation: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Show MeSH
Related in: MedlinePlus